Beihai Kangcheng is authorized by av203

On March 21, Beihai Kangcheng obtained the exclusive right to manufacture, develop and market the global (except North America) targeted monoclonal antibody av203 (can017) for the treatment of malignant tumors The transfer will bring a second clinical stage of targeted biological drugs to Beihai Kangcheng, and is also expected to bring cash income of up to $133 million to Aveo On March 21, 2016, Beihai Kangcheng (Beijing) Pharmaceutical Technology Co., Ltd (hereinafter referred to as "Beihai Kangcheng") and American Aveo Oncology (hereinafter referred to as "Aveo") jointly announced that they had signed an exclusive technology transfer agreement for the global (except North America) production, R & D and listing of targeted monoclonal antibody av203 (can017) for the treatment of malignant tumors Av203 (can017) is an anti erbb-3 (HER-3) monoclonal antibody in the clinical stage of Aveo R & D product line This is the first mAb drug of Beihai Kangcheng with global development and marketing rights The first indication explored and verified by the company is esophageal cancer According to the data, 80% of the world's esophageal cancer patients are in Asia, and 53% of them are in China According to the terms of the agreement, if the product development and launch are successful, Aveo will receive up to $133 million in cash including $1 million down payment, milestone payment and reimbursement At the same time, Aveo is also expected to receive a sales share that could be as high as a double-digit percentage Hokkaido Kangcheng will be fully responsible for the global production of av203 (can017), as well as the R & D and listing in the power area Beihai Kangcheng will undertake a series of pre clinical and clinical research and development costs, including the phase IIa trial to verify the efficacy of av203 (can017) in the treatment of esophageal squamous cell carcinoma After that, it is possible for Beihai Kangcheng and Aveo to reach an agreement to jointly develop av203 (can017), and both parties will respectively invest corresponding proportion of R & D expenses in their respective right areas If the two parties fail to reach an agreement on the next joint development plan, Hokkaido Kangcheng has the right to continue to develop av203 (can017) outside North America   "This harvest of av203 development and marketing license set a precedent for Beihai Kangcheng to expand markets outside Asia," said Dr Xue Qun, founder and chief executive officer of Beihai Kangcheng "Preclinical research data show that av203 (can017) is a high-quality potential treatment drug for esophageal squamous cell carcinoma, which is the most common pathological type of esophageal cancer in Asia, and also in development The main pathological types of esophageal cancer in many other countries, including countries As the starting point of the global development strategy of Hokkaido Kangcheng, we plan to start the research and development of av203 (can017) in Asia first, and then gradually promote it to other markets without effective treatment of esophageal squamous cell carcinoma " "More and more clinical data show that ERBB3 signal pathway driven by neuroregulatory protein-1 is activated in a series of tumors with high expression of HER3, which makes tumors resistant to standard treatment," Michael, CEO and President of Aveo Bailey said, "signing this agreement with Beihai Kangcheng, a mission oriented partner, and using their advantages can further promote the research and development process of av203 The core team of Beihai Kangcheng brings together senior executives with industry experience from original jianzan, synageva and other leading innovation companies What's more, we reserve the right to develop and market av203 in North America, so that when tivozanib, our leading product, is about to be launched in North America, we have the opportunity to obtain high-quality candidate drugs in the third stage of clinical research and development, which makes the Aveo tumor treatment product line stronger " About Beihai Kangcheng Beihai Kangcheng is an innovative pharmaceutical technology enterprise headquartered in Beijing, China By connecting the world's largest life high-tech pharmaceutical product line with the world's fastest-growing and potential application market, we can accelerate the marketization of high-end and special effect pharmaceutical products in China and Asia The core competitiveness of Beihai Kangcheng is not only reflected in the world-class consultants and management teams, but also compared with other enterprises in the same industry, the ability of Beihai Kangcheng to select, evaluate and obtain high-quality projects, the ability of project implementation and management, and the scientific research strength of clinical development all show its superior advantages For more information, please visit: www.canbridgepharma.com 2 about Aveo Aveo, an American biopharmaceutical company, which is committed to the research, development and marketing of anti-tumor candidate drugs, as well as the development of unmet medical needs in other health fields The company focuses on the development and commercialization of its leading candidate drug, tivozanib, an effective, specific, long half-life vascular endothelial growth factor inhibitor 1, 2 and 3 receptor, for the treatment of renal cell carcinoma and other cancers in North America Aveo uses a number of cooperative development and commercialization tivozanib to develop non tumor indications in the world and tumor indications outside the North American region, and simultaneously promote its product line of innovative anti-cancer and treatment of cachexia (consumption syndrome) For more information, go to: www.aveonology.com